Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP: Difference between revisions

From Commons Based Research
Jump to navigation Jump to search
Line 1: Line 1:
== What are the 10 biggest for-profit companies in this field?==
== What are the 10 biggest for-profit companies in this field?==


''Note on outputs: all these companies make their money primarily through developing and patenting drugs. The distinguishing factor seems to be that the largest of these companies produce the drugs themselves, while the smaller ones license these drugs to be produced by larger pharmaceutical companies''
Amgen


{| border=1 class="prettytable"
Genentech
|
| '''2006 Revenue ($m)'''
| '''Headquarters'''
| '''Primary Outputs'''
| '''Instances of Commons-based approaches'''


|-
Genzyme
| Amgen
| <div align="center">14268</div>
| Thousand Oaks, California
| ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline
| Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed


|-
Gilead Sciences
| Genentech


Biogen Idec


Cephalon


| <div align="center">9284</div>
MedImmune


Celgene


Abraxis BioScience


| South San Francisco
ImClone Systems


For more information on these companies, see [[BGP Table of Biggest For-Profit Companies]]


| synthetic human insulin - their first famous product, many others produced using the Boyer-Cohen rDNA process
| ?
|-
| Genzyme
| <div align="center">3187</div>
| Cambridge, Massachusetts
| Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue
| ?
|-
| Gilead Sciences
| <div align="center">3026</div>
| Foster City, California
| 11 commercial products
| ?
|-
| Biogen Idec
| <div align="center">2683</div>
| Cambridge, Massachusetts
| Treatments for Crohn's disease, non-Hodgkin's lymphoma, and multiple sclerosis
| Biogen outsources analyzing clinical trial data to other research labs (Powell pp. 72). Perhaps some of these exhibit commons-like behavior
|-
| Cephalon
| <div align="center">1764</div>
| Frazer, Pennsylvania
| Specializes in treating neurodegenerative diseases
| ?
|-
| MedImmune
| <div align="center">1277</div>
| Gaithersburg, Maryland
| Only major drug prevents respiratory diseases in infants
| ?
|-
| Celgene
| <div align="center">899</div>
| Summit, New Jersey
| treatments for erythema nodosum leprosum ("ENL") and multiple myeloma
| ?
|-
| Abraxis BioScience
| <div align="center">766</div>
| Los Angeles, California
| uses patented nanoparticle technology to produce products for metastatic breast cancer
| ?
|-
| ImClone Systems
| <div align="center">678</div>
| New York, New York
| acquired by Eli Lilly, tried to produce Erbitux for Colorectal Cancer, but failed to win FDA approval
| ?
|}
==How is the market distributed?==
==How is the market distributed?==
==Are there any incentives for specific locations?==
==Are there any incentives for specific locations?==

Revision as of 18:08, 11 April 2009

What are the 10 biggest for-profit companies in this field?

Amgen

Genentech

Genzyme

Gilead Sciences

Biogen Idec

Cephalon

MedImmune

Celgene

Abraxis BioScience

ImClone Systems

For more information on these companies, see BGP Table of Biggest For-Profit Companies

How is the market distributed?

Are there any incentives for specific locations?

Correlate them with their main outputs (Data. Narratives. Tools)

BGP Company Profiles - Data

NIH

Celera

Amgen

Genentech

Genzyme

Gilead Sciences

Biogen Idec

Cephalon

MedImmune

Celgene

Abraxis BioScience

ImClone Systems

BGP Company Profiles - Narratives

Elsevier

PubMed

Nature

Springer

BioMedCentral

BGP Company Profiles - Tools



Navigation

Bibliography for Item 6 in BGP
Biotechnology_-_Genomic_and_Proteomics

Retrieved from "http://cyber.harvard.edu/commonsbasedresearch/?title=Biotechnology_-_Genomic_and_Proteomics/IP_Profile_of_Biggest_for-profit_companies_in_BGP&oldid=1214"